ERBB2 and breast carcinoma: Although the progression-free survival and overall survival of Ramucirumab + Taxol group trended to be prolonged compared to the control group in the phase III clinical trials of HER2− advanced breast cancer, but it was disappointing that there was no statistical significance [8].